Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
10.1002/pros.23753 [DOI] [PubMed] [Google Scholar] Izumi, K
BPC-157 Peptide Sciences ,
Results accelerate in months 23 as your body adapts and you settle into consistent eating patterns
The FDA-approved weight loss medication Wegovy is indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition